Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Trubion Announces Positive Data From A Phase 1 / 2 Study Of TRU-016 For The Treatment Of Chronic Lymphocytic Leukemia (CLL)
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced the presentation of encouraging Phase 1 safety and efficacy results following administration of low doses of TRU-016 in heavily pre-treated patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company"s proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate.
generic viagra online
More Vigilant Monitoring For Seizures Among ICU Patients Encouraged
Two new studies published by neurologists at Columbia University Medical Center and NewYork-Presbyterian Hospital demonstrate a need for more vigilant monitoring for seizure activity among intensive care patients who may be experiencing subtle seizures that are typically unrecognized. These subtle seizures may be affecting patients" prognoses and causing long-term brain damage, death and severe disability.
News of the day
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-based chemotherapy agent and the Company"s lead product candidate. The Company worked collaboratively with the U.S. Food and Drug Administration (FDA) to design this study, which is required for new chemical entities.
Sexual Health

InVitria To Unveil Powerful Cell Culture Media Component ZAP-CHO

InVitria"s Director of Cell Culture, Dr. Steve Pettit, will present the performance enhancing features of ZAP-CHO, a new media component for Chinese hamster ovary (CHO) cell culture, at 3:30 pm on Wednesday, May 20, 2009 as part of BioProcess International"s BioProcess Theatre, a venue employed to facilitate the sharing of advances and discoveries in the biopharmaceutical sector. ZAP-CHO, a new product from InVitria , enhances performance of mammalian cell culture including improved cell growth and antibody production. It achieves these performance advantages in chemically defined media that are completely free of animal components. Previously, the performance seen with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum), BSA (bovine serum albumin) or plasma-derived HSA (human serum albumin) in cell culture media. "Our team of scientists has developed supplements that not only meet the regulatory requirements of researchers using hybridoma and CHO cell culture, but it exceeds their performance expectations as well," said Dr. Pettit. "InVitria products have been utilized by customers to successfully achieve greater cell productivity and growth; faster cell doublings; and improved consistency." InVitria"s other leading cell culture media supplements will also be part of the BIO Process Product Zone exhibition in Booth #5120 within the BIO 2009 International Convention from May 19-21. These supplements include: * Albumin-DX -whether you have problems with non-specific binding, biomarker stability, consistency or regulatory requirements, Albumin-DX was designed to answer the most difficult assay challenges. * Cellastim -Cellastim outperforms plasma-derived albumin, bovine serum albumin and other s of recombinant albumin. * Lacromin -Lacromin is a CHO growth-factor that outperforms insulin and IGF-1. InVitria


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009